通力律师事务所近日为上海复宏汉霖生物技术公司完成港交所首次公开发行提供了法律意见，此次上市共筹集了4.1亿美元资金。
通力之外，为复宏汉霖上市提供法律意见的国际律所为富而德律师事务所，保荐人的服务律所为嘉源律师事务所及盛德律师事务所。
复宏汉霖成立于2010年，是复星国际下属复星医药所拆分的子公司。根据路透社报道，复宏汉霖的联合创始人刘世高原任职于美国制药巨头安进公司，复宏汉霖主要研发生产针对肿瘤及自身免疫性疾病的新药和生物类似药。根据招股书，除今年2月已在中国上市的首款生物类似药外，其现有20余种处于不同研发阶段的药物。
路透社补充说，复宏汉霖此次上市，也是对港交所投资者胃口的一次“试水”。港交所今年第三季度新股发行量明显下滑，8月只有一支新股上市。根据港交所网站，复宏汉霖之后，鑫苑物业和百威亚太都将于9月底上市。
根据富而德的一篇新闻稿，复宏汉霖上市募集资金将被用于药物临床试验，以及新药的审批流程。
通力团队的牵头律师为合伙人陈臻和张征轶，富而德的牵头律师为合伙人黄颖慧和Arun Balasubramanian。
Llinks, Freshfields advise drugmaker Henlius on $410 mln Hong Kong IPO
Llinks Law Offices and Freshfields Bruckhaus Deringer have represented Shanghai Henlius Biotech on its $410 million Hong Kong initial public offering, with Jia Yuan Law Offices and Sidley Austin advising the sponsors.
Backed by Chinese conglomerate Fosun International , Henlius is a biotech company which develops new drugs and biosimilars. According to its IPO prospectus, apart from one biosimilar product commercially launched in China, the company’s drug portfolio covers over 20 other products in various stages of clinical development.
Reuters added that the Henlius IPO was seen as a test for investor appetite in Hong Kong, with the IPO of Budweiser Brewing APAC, Asia’s largest listing this year, also happening at the end of September.
The Llinks team was led by partners Chen Zhen and Zhang Zhengyi, while the Freshfields team was led by partners Grace Huang and Arun Balasubramanian.
Bank of America Merrill Lynch, CICC, Citigroup and CMB International are among the deal’s sponsors.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
